176 related articles for article (PubMed ID: 10367748)
1. Plasma pharmacokinetics of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in a phase I trial.
Kestell P; Dunlop IC; McCrystal MR; Evans BD; Paxton JW; Gamage RS; Baguley BC
Cancer Chemother Pharmacol; 1999; 44(1):45-50. PubMed ID: 10367748
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of the cytotoxic agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
McCrystal MR; Evans BD; Harvey VJ; Thompson PI; Porter DJ; Baguley BC
Cancer Chemother Pharmacol; 1999; 44(1):39-44. PubMed ID: 10367747
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in cancer patients undergoing a phase I clinical trial.
Schofield PC; Robertson IG; Paxton JW; McCrystal MR; Evans BD; Kestell P; Baguley BC
Cancer Chemother Pharmacol; 1999; 44(1):51-8. PubMed ID: 10367749
[TBL] [Abstract][Full Text] [Related]
4. Extravascular transport of the DNA intercalator and topoisomerase poison N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (DACA): diffusion and metabolism in multicellular layers of tumor cells.
Hicks KO; Pruijn FB; Baguley BC; Wilson WR
J Pharmacol Exp Ther; 2001 Jun; 297(3):1088-98. PubMed ID: 11356933
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II. CRC Phase I/II Committee.
Twelves CJ; Gardner C; Flavin A; Sludden J; Dennis I; de Bono J; Beale P; Vasey P; Hutchison C; Macham MA; Rodriguez A; Judson I; Bleehen NM
Br J Cancer; 1999 Aug; 80(11):1786-91. PubMed ID: 10468297
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
7. Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes.
Saleem A; Aboagye EO; Matthews JC; Price PM
Cancer Chemother Pharmacol; 2008 Apr; 61(5):865-73. PubMed ID: 17639391
[TBL] [Abstract][Full Text] [Related]
8. Studies on the metabolism of the novel antitumor agent [N-methyl-11C]N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trials.
Osman S; Luthra SK; Brady F; Hume SP; Brown G; Harte RJ; Matthews JC; Denny WA; Baguley BC; Jones T; Price PM
Cancer Res; 1997 Jun; 57(11):2172-80. PubMed ID: 9187117
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM
J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741
[TBL] [Abstract][Full Text] [Related]
10. Comparative biodistribution and metabolism of carbon-11-labeled N-[2-(dimethylamino)ethyl]acridine-4-carboxamide and DNA-intercalating analogues.
Osman S; Rowlinson-Busza G; Luthra SK; Aboagye EO; Brown GD; Brady F; Myers R; Gamage SA; Denny WA; Baguley BC; Price PM
Cancer Res; 2001 Apr; 61(7):2935-44. PubMed ID: 11306471
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomography.
Saleem A; Harte RJ; Matthews JC; Osman S; Brady F; Luthra SK; Brown GD; Bleehen N; Connors T; Jones T; Price PM; Aboagye EO
J Clin Oncol; 2001 Mar; 19(5):1421-9. PubMed ID: 11230487
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II.
Bridewell DJ; Finlay GJ; Baguley BC
Cancer Chemother Pharmacol; 1999; 43(4):302-8. PubMed ID: 10071981
[TBL] [Abstract][Full Text] [Related]
13. A phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patients.
Grem JL; Harold N; Keith B; Chen AP; Kao V; Takimoto CH; Hamilton JM; Pang J; Pace M; Jasser GB; Quinn MG; Monahan BP
Clin Cancer Res; 2002 Jul; 8(7):2149-56. PubMed ID: 12114415
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
Tranchand B; Catimel G; Lucas C; Sarkany M; Bastian G; Evene E; Guastalla JP; NĂ©grier S; Rebattu P; Dumortier A; Foy M; Grossin F; Mazier B; Froudarakis M; Barbet N; Clavel M; Ardiet C
Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
[TBL] [Abstract][Full Text] [Related]
15. Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000.
Propper DJ; de Bono J; Saleem A; Ellard S; Flanagan E; Paul J; Ganesan TS; Talbot DC; Aboagye EO; Price P; Harris AL; Twelves C
J Clin Oncol; 2003 Jan; 21(2):203-10. PubMed ID: 12525511
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1.
Foster BJ; Wiegand RA; LoRusso PM; Baker LH
Clin Cancer Res; 1995 Aug; 1(8):831-7. PubMed ID: 9816052
[TBL] [Abstract][Full Text] [Related]
17. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
Supko JG; Balcerzak SP; Kraut EH
Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
[TBL] [Abstract][Full Text] [Related]
18. Cellular uptake of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
Haldane A; Finlay GJ; Hay MP; Denny WA; Baguley BC
Anticancer Drug Des; 1999 Jun; 14(3):275-80. PubMed ID: 10500502
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).
LoRusso P; Foster BJ; Poplin E; McCormick J; Kraut M; Flaherty L; Heilbrun LK; Valdivieso M; Baker L
Clin Cancer Res; 1995 Dec; 1(12):1487-93. PubMed ID: 9815948
[TBL] [Abstract][Full Text] [Related]
20. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]